‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors

LBA28CARFILZOMIB (K) VS LOW-DOSE CORTICOSTEROIDS AND OPTIONAL CYCLOPHOSPHAMIDE (CY) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 3 STUDY (FOCUS)

(2017) H. Ludwig et al.   ANNALS OF ONCOLOGY

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

(2015) Kyriakos P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study

(2015) Klaus Murbraech et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms

(2015) Neil K. Taunk et al.   Frontiers in Oncology

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

(2014) S. Bringhen et al.   BLOOD

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

(2014) Ajai Chari et al.   BMC CANCER

The challenge of cross-trial comparisons using limited data

(2014) J. P. Laubach et al.   HAEMATOLOGICA

Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000

(2014) D. S. Siegel   HAEMATOLOGICA

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

(2014) J R Berenson et al.   LEUKEMIA

Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy

(2013) Dan Liu et al.   Circulation-Cardiovascular Imaging

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

(2013) T. M. Herndon et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Primary proteasome inhibition results in cardiac dysfunction

(2013) Joerg Herrmann et al.   EUROPEAN JOURNAL OF HEART FAILURE

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database

(2013) Benjamin Honton et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

(2010) Dominika Nowis et al.   AMERICAN JOURNAL OF PATHOLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE